Published in Chest on July 01, 2012
Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis (2014) 2.07
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 2.66
Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw (2011) 0.94
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation (2012) 3.74
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med (2008) 2.51
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res (2007) 1.87
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85
Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm (2005) 1.81
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol (2003) 1.67
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost (2011) 1.61
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am (2005) 1.59
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood (2004) 1.55
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther (2004) 1.30
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost (2005) 1.27
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25
The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 1.25
Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14
Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14
Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol (2009) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost (2008) 1.12
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11
15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes. Blood (2008) 1.11
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang (2011) 1.11
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood (2005) 1.10
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost (2011) 1.07
Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost (2012) 1.07